HH101785
/ HaiHe Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 07, 2025
…Haihe Biopharma (Haihe), announced that the company’s self-developed selective PARP1 inhibitor (R&D code: HH101785) with full intellectual property rights has been approved by the National Medical Products Administration (NMPA) to carry out clinical trials and is intended to be used in Advanced Malignant Solid Tumors.
(Haihe Biopharma Press Release)
New trial • Solid Tumor
1 to 1
Of
1
Go to page
1